ARPC1B and familial pancreatic carcinoma: Furthermore, a total of 852 PDAC patients from a multicenter‐derived meta‐cohort (Kaplan–Meier Plotter platform, https://kmplot.com/analysis/) [9] were included and analysed, and we observed that patients with higher ARPC1B expression exhibited significantly shorter overall survival (HR = 1.25, p < 0.01), which further indicated ARPC1B as a potential biomarker of poor prognosis and a promising therapeutic target for pancreatic cancer (Figure 1P).